A phase <scp>II</scp> trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre <scp>GOAL</scp> trial-Reference-Cited by-同舟云学术

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial

Published:2022-04 Issue:3 Volume:198 Page:482-491
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Hess Georg¹^ORCID,Hüttmann Andreas²^ORCID,Witzens‐Harig Mathias³,Dreyling Martin H.⁴,Keller Ulrich⁵,Marks Reinhard⁶,Ernst Thomas⁷,Pott Christiane⁸,Viardot Andreas⁹,Frontzek Fabian¹⁰,Trautmann Marcel¹¹,Ruckes Christian¹²,Deuster Oliver¹²,Rosenwald Andreas¹³,Theobald Matthias¹,Lenz Georg¹⁰

Affiliation:

1. Department of Internal Medicine III University Medical Center of the Johannes Gutenberg University Mainz Germany

2. Department of Hematology University Hospital Essen, West German Cancer Center, University of Duisburg‐Essen Essen Germany

3. Department of Internal Medicine V University Hospital Heidelberg Heidelberg Germany

4. Department of Internal Medicine III Ludwig‐Maximilians University of Munich Munich Germany

5. Internal Medicine III Technical University of Munich Munich Germany

6. Department of Hematology/Oncology and Stem Cell Transplantation University Medical Center Freiburg Germany

7. Department of Internal Medicine II Jena University Hospital Jena Germany

8. Department of Internal Medicine II University of Schleswig‐Holstein Kiel Germany

9. Department of Internal Medicine III University Hospital Ulm Ulm Germany

10. Department of Medicine A University Hospital Münster Münster Germany

11. Division of Translational Pathology, Gerhard Domagk Institute of Pathology Münster University Hospital Münster Germany

12. Interdisciplinary Center for Clinical Trials (IZKS) University Medical Center of the Johannes Gutenberg University Mainz Germany

13. Department of Pathology University of Würzburg Würzburg Germany

Funder

CTI Biopharma

Roche

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18161

Reference31 articles.

1. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

3. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

5. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

2. Host heparan sulfate promotes ACE2 super-cluster assembly and enhances SARS-CoV-2-associated syncytium formation;Nature Communications;2023-09-18

3. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis;Cancer Research and Treatment;2023-07-15

4. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-06

5. Long‐term efficacy in patients with relapsed/refractory diffuse large B‐cell lymphoma achieving a complete response with pixantrone;European Journal of Haematology;2023-05-10